ES2930077T3 - Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria - Google Patents

Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria Download PDF

Info

Publication number
ES2930077T3
ES2930077T3 ES17704039T ES17704039T ES2930077T3 ES 2930077 T3 ES2930077 T3 ES 2930077T3 ES 17704039 T ES17704039 T ES 17704039T ES 17704039 T ES17704039 T ES 17704039T ES 2930077 T3 ES2930077 T3 ES 2930077T3
Authority
ES
Spain
Prior art keywords
surgery
apelin
subject
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17704039T
Other languages
English (en)
Spanish (es)
Inventor
Philippe Valet
Cédric Dray
Vincent Minville
Bernard Frances
François Labaste
Claire Vinel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Toulouse
Université de Toulouse
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Toulouse
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Toulouse, Universite Toulouse III Paul Sabatier filed Critical Institut National de la Santé et de la Recherche Médicale
Application granted granted Critical
Publication of ES2930077T3 publication Critical patent/ES2930077T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17704039T 2016-02-15 2017-02-14 Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria Active ES2930077T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305170 2016-02-15
PCT/EP2017/053308 WO2017140684A2 (en) 2016-02-15 2017-02-14 Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction

Publications (1)

Publication Number Publication Date
ES2930077T3 true ES2930077T3 (es) 2022-12-07

Family

ID=55359484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17704039T Active ES2930077T3 (es) 2016-02-15 2017-02-14 Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria

Country Status (5)

Country Link
US (3) US11484577B2 (cg-RX-API-DMAC7.html)
EP (1) EP3416688B1 (cg-RX-API-DMAC7.html)
JP (1) JP7063813B2 (cg-RX-API-DMAC7.html)
ES (1) ES2930077T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017140684A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020180823A1 (en) * 2019-03-01 2020-09-10 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of post-operative cognitive dysfunction
WO2021222438A1 (en) * 2020-04-28 2021-11-04 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress
WO2023211684A2 (en) * 2022-04-29 2023-11-02 Noetix Pharma Llc Prevention and treatment of post-operative cognitive dysfunction (pocd)
US20240238333A1 (en) * 2023-01-12 2024-07-18 Penland Foundation Treatment of delirium using nitrous oxide

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932667A (en) 1971-08-02 1976-01-13 Airco, Inc. Ether compound as an inhalation anesthetic
US3954893A (en) 1971-08-09 1976-05-04 W. R. Grace & Co. New halogenated cyclobutanes
US3987203A (en) 1973-03-16 1976-10-19 Airco, Inc. Anesthetizing composition and method
DE2340561C2 (de) 1973-08-10 1982-12-16 Hoechst Ag, 6000 Frankfurt 2.2.2-Trifluor-1-chloräthyl-äther und Verfahren zu ihrer Herstellung sowie Inhalations-Anästhetikum, das einen dieser Stoffe enthält
DE2340560C2 (de) 1973-08-10 1982-12-16 Hoechst Ag, 6000 Frankfurt 1.2.2.2-Tetrafluoräthyl-äther, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Inhalations-Anästhetikum
US3987100A (en) 1974-04-11 1976-10-19 E. I. Du Pont De Nemours And Company Cyclohexane oxidation in the presence of binary catalysts
US3949005A (en) 1974-05-09 1976-04-06 Airco, Inc. Hexafluoro-t-butyl-difluoromethyl ether as an inhalation anesthetic
US3931344A (en) 1974-08-22 1976-01-06 W. R. Grace & Co. Bromofluorocyclopropanes
US3932529A (en) 1974-12-26 1976-01-13 W. R. Grace & Co. Halocyclopropyl halomethyl ethers
US3995062A (en) 1974-12-26 1976-11-30 W. R. Grace & Co. Halocyclopropyl halomethyl ethers
US3932669A (en) 1975-01-10 1976-01-13 W. R. Grace & Co. 1-Chloro-2,2-dimethyl-1,4,4-trifluorocyclobutane as an anesthetics
US4220644A (en) 1976-05-03 1980-09-02 Smithkline Corporation 7-Acylamino-3-(substituted tetrazolyl thiomethyl) cephalosporins
US4281020A (en) 1979-03-01 1981-07-28 The Dow Chemical Company Deuterated analogues of methoxyflurane useful as an anesthetic
US4346246A (en) 1979-03-12 1982-08-24 Airco, Inc. Process for adjusting the halogen content of halogenated aliphatic ethers
US4262144A (en) 1979-10-25 1981-04-14 The Dow Chemical Company Deuterated isoflurane
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5391579A (en) 1993-01-28 1995-02-21 University Of Iowa Research Foundation Deuterated sevoflurane as an inhalational anesthetic
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
CN1283228A (zh) 1997-12-24 2001-02-07 武田药品工业株式会社 多肽、其生产方法及应用
US7635751B2 (en) 2000-03-23 2009-12-22 Takada Pharmaceutical Company Limited Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
US20050112701A1 (en) 2003-09-11 2005-05-26 Aventis Pharma Deutschland Gmbh Test system for the identification of APJ receptor ligands
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US9308232B2 (en) * 2006-06-05 2016-04-12 Keyview Labs, Inc. Compositions and methods for enhancing brain function
EP1903052A3 (en) 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
US20100113570A1 (en) 2008-04-23 2010-05-06 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US20120316247A1 (en) 2009-10-20 2012-12-13 The General Hospital Corporation Prevention and treatment of post-operative cognitive dysfunction (pocd)
DK2547363T3 (da) * 2010-02-17 2020-09-07 The Kennedy Trust For Rheumatology Res Fremgangsmåder til forebyggelse eller behandling af udløste inflammatoriske reaktioner med tumor nekrosis faktor alfa antagonist.
EP3780002B1 (en) * 2010-11-24 2024-07-17 Clinical Ink, Inc. Systems and methods to assess cognitive function
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP3907237A1 (en) 2012-12-20 2021-11-10 Amgen Inc. Apj receptor agonists and uses thereof
AU2014284496A1 (en) 2013-07-03 2016-01-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
GB201311948D0 (en) 2013-07-03 2013-08-14 British American Tobacco Co Curling Machine
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides

Also Published As

Publication number Publication date
JP2019508416A (ja) 2019-03-28
US20210196798A1 (en) 2021-07-01
JP7063813B2 (ja) 2022-05-09
US20230093887A1 (en) 2023-03-30
US11484577B2 (en) 2022-11-01
EP3416688A2 (en) 2018-12-26
EP3416688B1 (en) 2022-08-17
US11896649B2 (en) 2024-02-13
WO2017140684A2 (en) 2017-08-24
WO2017140684A3 (en) 2017-12-21
US20240226238A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
US11896649B2 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
Hu et al. Involvement of the blood–brain barrier opening in cognitive decline in aged rats following orthopedic surgery and high concentration of sevoflurane inhalation
ES2472737T3 (es) Usos m�dicos adicionales de la proteína antisecretora
ES2834598T3 (es) Histatina para la curación de heridas corneales y enfermedades de la superficie ocular
KR20200143407A (ko) Cgrp를 억제하는데 사용하기 위한 신경독소
JP2019059730A (ja) デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
PT2371865T (pt) ANTICORPOS QUE SE LIGAM À FOSFATASE TIROSINA DE PROTEÍNAS HUMANA BETA (FTPH-ß) E SUAS UTILIZAÇÕES
ES2653734T3 (es) Inhibidores de apoptosis y usos de los mismos
ES2702333T3 (es) Dispositivos para la médula espinal para promover la regeneración axonal
ES2827184T3 (es) Métodos de prevención o tratamiento de reacciones inflamatorias desencadenadas utilizando antagonista alfa del factor de necrosis tumoral
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
CN108472332B (zh) 用于通过经鼻施用来治疗中风的组合物
ES2210829T3 (es) Composicion y proceso inmunologico utilizados para modificar transitoriamente la melina del sistema nervioso central de mamiferos para estimular la regeneracion neuronal.
KR20240034761A (ko) Glp-1r 효능제를 포함하는 약제학적 조성물
US9873724B2 (en) Pro-angiogenic peptides and peptide conjugates
ES2247329T3 (es) Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales.
ES2842523T3 (es) Métodos y composiciones para el tratamiento de la artritis
ES2988478T3 (es) Agente profiláctico y/o terapéutico para la demencia
ES2427932T3 (es) Remedio para la degeneración de los discos intervertebrales
CN113288904B (zh) Mitoquinone在制备预防和/或治疗运动损伤的药物中的应用
ES3041501T3 (en) Hmgb1 derived peptide for treating or preventing a cartilage disorder
TWI611805B (zh) 用於治療坐骨神經損傷之醫藥組合物
CN118490681B (zh) 瑞香素在制备治疗淋巴回流障碍的药物中的应用
CN112274644A (zh) 一种用于治疗脊柱与骨关节病变并减轻其疼痛的药物
WO2011021832A2 (ko) 척수 손상 예방 또는 치료용 조성물